SHANXI C&Y PHARMACEUTICAL GROUP CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.73 CNY | +2.59% |
|
+7.78% | -9.35% |
| Sales 2022 | 829M 114M 156M | Sales 2023 | 799M 110M 151M | Capitalization | 2.33B 321M 439M |
|---|---|---|---|---|---|
| Net income 2022 | -119M -16.43M -22.46M | Net income 2023 | 25M 3.45M 4.72M | EV / Sales 2022 | 2 x |
| Net Debt 2022 | 24.97M 3.45M 4.71M | Net Debt 2023 | 135M 18.58M 25.4M | EV / Sales 2023 | 3.08 x |
| P/E ratio 2022 |
-13.5
x | P/E ratio 2023 |
92.3
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 19.32% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.59% | ||
| 1 week | +7.78% | ||
| Current month | -3.54% | ||
| 1 month | -3.32% | ||
| 3 months | +0.46% | ||
| 6 months | -9.63% | ||
| Current year | -9.35% |
1 week
7.83
8.98
1 month
7.6911.60
Current year
4.9811.60
1 year
4.9811.60
3 years
4.9813.04
5 years
4.9213.04
10 years
4.9254.57
| Managers | Title | Age | Since |
|---|---|---|---|
Qun Zhao
CEO | Chief Executive Officer | 53 | 05-02-28 |
Yan Jie He
DFI | Director of Finance/CFO | 42 | 10-11-30 |
Hai Rong Zhong
BRD | Director/Board Member | 65 | 15-03-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Qun Zhao
CEO | Chief Executive Officer | 53 | 05-02-28 |
Xu Hong Zhang
BRD | Director/Board Member | 53 | 05-02-28 |
Jun Xian Yu
BRD | Director/Board Member | 57 | 05-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 8.73 | +2.59% | 13,538,620 |
| 24-04-25 | 8.51 | +5.85% | 14,258,620 |
| 24-04-24 | 8.04 | -1.71% | 9,624,540 |
| 24-04-23 | 8.18 | +3.94% | 7,783,200 |
| 24-04-22 | 7.87 | -2.84% | 8,847,717 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
ShanXi C&Y Pharmaceutical Group Co., Ltd. is principally engaged in the research, development, manufacture and distribution of pharmaceuticals. The Companyâs main products include anti-infective agents, respiratory system agents, cardiovascular drugs, antidepressant drugs, urinary system agents, pediatric agents and other drugs, as well as pharmaceutical raw materials and pharmaceutical intermediates. It also involves in the manufacture and distribution of health food products, as well as the provision of deoxyribonucleic acid (DNA) genetic preservation and pregnant environment testing services. The Company distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
| 1st Jan change | Capi. | |
|---|---|---|
| -9.35% | 291M | |
| +26.58% | 661B | |
| +27.40% | 566B | |
| -6.32% | 352B | |
| +20.30% | 332B | |
| +3.21% | 283B | |
| +14.13% | 231B | |
| +5.17% | 200B | |
| -9.04% | 195B | |
| -4.90% | 145B |
- Stock Market
- Equities
- 300254 Stock
